[Asthma-COPD overlap syndrome among patients with stable COPD]

Understanding the overlap between asthma and COPD remains a challenge in respiratory medicine. Prior research has shown that both conditions share symptoms and pathophysiology, but distinguishing them is essential for treatment. No prior work had resolved how frequently asthma and COPD coexist in stable COPD patients. This uncertainty drove the need to explore the overlap syndrome in a clinical setting. Researchers have already identified that COPD is characterized by airflow obstruction, while asthma involves bronchial hyperresponsiveness. However, the diagnostic criteria for overlap remain unclear. That uncertainty motivated this study to examine the frequency and traits of overlap syndrome in COPD patients. The gap in knowledge about the clinical significance of this overlap remains significant. This study aimed to address that gap by analyzing a specific patient cohort.

This study aimed to describe the frequency and clinical characteristics of the asthma-COPD overlap syndrome in patients with stable COPD. Researchers sought to determine how often this overlap occurs and what features distinguish these patients from those with pure COPD. The specific problem addressed was the lack of clarity regarding the overlap syndrome's prevalence and its clinical implications. The motivation came from the need to better understand how asthma traits affect COPD patients. The authors proposed that overlap patients might have distinct symptom profiles despite similar levels of airway obstruction. They also wanted to assess whether immune-inflammatory markers differ between groups. The study focused on patients with GOLD stages 2 to 4 COPD. The goal was to provide evidence-based insights into the overlap syndrome's clinical relevance.

The study included 46 patients with stable COPD recruited from an outpatient clinic. Researchers used a combination of clinical history and functional and inflammatory markers to define the overlap syndrome. Post-bronchodilation FEV1/FVC < 70% was a primary criterion. Additional traits included FEV1 reversibility, eosinophilic inflammation, and allergy markers. The team collected sputum and blood samples to assess eosinophil levels. They also measured FENO (fractional exhaled nitric oxide) to evaluate airway inflammation. Clinical assessments included CAT scores to evaluate symptom severity. The study compared overlap syndrome patients with those diagnosed with pure COPD. This approach allowed researchers to identify distinct features of the overlap group.

Approximately 37% of COPD patients met the criteria for the overlap syndrome. These patients had significantly higher CAT scores (24.6 ± 8.1) compared to the pure COPD group (19.4 ± 8). Despite similar levels of airway obstruction, overlap patients reported more severe symptoms. The DLCO/VA transfer coefficient was preserved in the overlap group (97 ± 24%) but reduced in pure COPD patients (80 ± 20%). Eosinophilic inflammation was more common in the overlap group, with sputum eosinophils ≥ 3%. Blood eosinophils ≥ 400/μl and FENO ≥ 45 ppb were also more frequent. FEV1 reversibility was observed in overlap patients, indicating bronchodilator response. These findings suggest that overlap syndrome is a distinct subgroup within COPD.

The authors concluded that approximately one-third of stable COPD patients meet the criteria for the asthma-COPD overlap syndrome. These patients exhibit higher symptom severity as measured by CAT scores. Despite similar airway obstruction, they show distinct inflammatory and functional traits. The DLCO/VA coefficient was preserved in the overlap group but reduced in pure COPD patients. The presence of asthma traits, such as FEV1 reversibility and eosinophilic inflammation, was more common in the overlap group. The study suggests that overlap syndrome is clinically relevant and may require different management strategies. The findings support the need for further research into the diagnostic criteria and treatment approaches for this subgroup. The authors propose that recognizing overlap syndrome could improve patient outcomes.